Clearside Biomedical (NASDAQ:CLSD – Get Free Report) announced its earnings results on Monday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04, Yahoo Finance reports. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter in the previous year, the company earned ($0.15) EPS.
Clearside Biomedical Price Performance
NASDAQ:CLSD opened at $1.07 on Wednesday. The business has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $1.32. Clearside Biomedical has a 1 year low of $0.65 and a 1 year high of $2.12. The company has a market capitalization of $79.96 million, a P/E ratio of -1.94 and a beta of 2.43.
Analyst Upgrades and Downgrades
Several brokerages recently commented on CLSD. Oppenheimer started coverage on Clearside Biomedical in a research report on Tuesday, June 25th. They set an “outperform” rating and a $5.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Clearside Biomedical in a report on Tuesday. StockNews.com lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, May 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price target on shares of Clearside Biomedical in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.60.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
- Five stocks we like better than Clearside Biomedical
- Compound Interest and Why It Matters When Investing
- How to Invest in Mutual Funds
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- How Investors Can Find the Best Cheap Dividend Stocks
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
